A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(28 sites)

United States

Glaukos Investigative Site, Dothan, Alabama

Glaukos Investigative Site, Petaluma, California

Glaukos Investigative Site, Torrance, California

Glaukos Investigative Site, Colorado Springs, Colorado

Glaukos Investigative Site, Grand Junction, Colorado

Glaukos Investigative Site, Bradenton, Florida

Glaukos Investigative Site, Fort Myers, Florida

Glaukos Investigative Site, South Miami, Florida

Glaukos Investigative Site, Atlanta, Georgia

Glaukos Investigative Site, Carmel, Indiana

Glaukos Investigative Site, Fraser, Michigan

Glaukos Investigative Site, Kansas City, Missouri

Glaukos Investigative Site, Palisades Park, New Jersey

Glaukos Investigative Site, Shelby, North Carolina

Glaukos Investigative Site, Bala-Cynwyd, Pennsylvania

Glaukos Investigative Site, Nashville, Tennessee

Glaukos Investigative Site, Houston, Texas

Glaukos Investigative Site, San Antonio, Texas

Glaukos Investigative Site, Madison, Wisconsin

Glaukos Investigative Site, Milwaukee, Wisconsin

Germany

Glaukos Investigative Site, Mainz

Glaukos Investigative Site, München

Italy

Glaukos investigative Site, Messina

Spain

Glaukos Investigative Site, Barcelona

Glaukos Investigative Site, Madrid

Glaukos Investigative Site, Seville

Glaukos Investigative Site, Zaragoza